The promise and perils of HDAC inhibitors in neurodegeneration. Alessandro Didonna and
Puneet Opal; Annals of Clinical and Translational Neurology, Volume 2, Issue 1, pages 79–101, January 2015 DOI: 10.1002/acn3.147
OPEN ACCESS
Tuesday, February 3, 2015
Saturday, January 31, 2015
International Congress on Friedreich’s Ataxia and International conference on “DNA Structure in Health & Disease”
International Congress on Friedreich’s Ataxia and International conference on “DNA Structure in Health & Disease”.; 11th -13th April, 2015 at the All India Institute of Medical Sciences, New Delhi, India.
Friday, January 30, 2015
Frataxin inactivation leads to steroid deficiency in flies and human ovarian cells
Frataxin inactivation leads to steroid deficiency in flies and human ovarian cells . Amandine Palandri, David L'hôte, Joëlle Cohen-Tannoudji, Hervé Tricoire and Véronique Monnier; Hum. Mol. Genet. (2015) doi: 10.1093/hmg/ddv024 First published online: January 26, 2015
Reata Enrolls First Patient in the MOXIe Study, a Phase 2/3 Study Examining RTA 408 in Friedreich's Ataxia Patients
Reata Enrolls First Patient in the MOXIe Study, a Phase 2/3 Study Examining RTA 408 in Friedreich's Ataxia Patients. SOURCE: Reata Pharmaceuticals, Inc., January 29
IRVING, TX--(Marketwired - January 29, 2015) - Reata announces enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Oral Capsules versus placebo for the treatment of patients with Friedreich's ataxia.
IRVING, TX--(Marketwired - January 29, 2015) - Reata announces enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Oral Capsules versus placebo for the treatment of patients with Friedreich's ataxia.
Tuesday, January 27, 2015
Project: Elucidating the molecular basis of gene silencing by an ORC-HP1 interaction and their contribution to human health disorders
Project: Elucidating the molecular basis of gene silencing by an ORC-HP1 interaction and their contribution to human health disorders. Principal Investigator: Christian Speck, Imperial College London, Department Name: Institute of Clinical Sciences. Funded Period: sep 14 - ago 17
We will analyse the effect of ORC-HP1 interactions for its normal role in cells and in the context of the epigenetic disease, Friedreich's Ataxia, to understand the functional relevance of the complex.
We will analyse the effect of ORC-HP1 interactions for its normal role in cells and in the context of the epigenetic disease, Friedreich's Ataxia, to understand the functional relevance of the complex.
Neurodegenerative Diseases and Therapeutic Strategies using Iron chelators
Neurodegenerative Diseases and Therapeutic Strategies using Iron chelators. Roberta J. Ward, David T. Dexter, Robert R. Crichton, Journal of Trace Elements in Medicine and Biology, Available online 22 January 2015, ISSN 0946-672X, http://dx.doi.org/10.1016/j.jtemb.2014.12.012.
Preliminary results from trials of iron chelation therapy in these neurodegenerative diseases is reviewed.
Preliminary results from trials of iron chelation therapy in these neurodegenerative diseases is reviewed.
Genome-Engineering Tools to Establish Accurate Reporter Cell Lines That Enable Identification of Therapeutic Strategies to Treat Friedreich’s Ataxia
Genome-Engineering Tools to Establish Accurate Reporter Cell Lines That Enable Identification of Therapeutic Strategies to Treat Friedreich’s Ataxia. Rodrigo Villaseñor, Loren Miraglia, Angelica Romero, Buu Tu, Tanel Punga, Philip Knuckles, Stephan Duss, Tony Orth, and Marc Bühler; J Biomol Screen 1087057114568071, first published on January 23, 2015 as doi:10.1177/1087057114568071
Rational design of small-molecule inhibitors of the identified frataxin repressors and/or high-throughput screening of large siRNA or compound libraries with our system may yield treatments for Friedreich’s ataxia.
Rational design of small-molecule inhibitors of the identified frataxin repressors and/or high-throughput screening of large siRNA or compound libraries with our system may yield treatments for Friedreich’s ataxia.
Monday, January 26, 2015
Cerebellar transcriptional alterations with Purkinje cell dysfunction and loss in mice lacking PGC-1α
Cerebellar transcriptional alterations with Purkinje cell dysfunction and loss in mice lacking PGC-1α. Lucas EK, Reid CS, McMeekin LJ, Dougherty SE, Floyd CL, Cowell RM. Front Cell Neurosci. 2015 Jan 6;8:441. doi: 10.3389/fncel.2014.00441. eCollection 2014.
OPEN ACCESS
Recently, PGC-1α was also found to be involved in the pathology of Friedreich Ataxia. Friedreich Ataxia is an autosomal recessive disorder and is the most common of the early-onset hereditary ataxias. Friedreich Ataxia is caused by an expanded GAA triplet repeat in the first intron of the frataxin gene, resulting in a 65–95% reduction in frataxin expression in Friedreich Ataxia patients . Transcript expression of PGC-1α and its downstream target MnSOD was found to be decreased in fibroblasts and lymphoblasts of patients with Friedreich Ataxia. In fact, transcript expression of frataxin is highly correlated with that of PGC-1α in Friedreich Ataxia and control cells, and knock down of frataxin in cell culture also decreases transcript expression of PGC-1α.
OPEN ACCESS
Recently, PGC-1α was also found to be involved in the pathology of Friedreich Ataxia. Friedreich Ataxia is an autosomal recessive disorder and is the most common of the early-onset hereditary ataxias. Friedreich Ataxia is caused by an expanded GAA triplet repeat in the first intron of the frataxin gene, resulting in a 65–95% reduction in frataxin expression in Friedreich Ataxia patients . Transcript expression of PGC-1α and its downstream target MnSOD was found to be decreased in fibroblasts and lymphoblasts of patients with Friedreich Ataxia. In fact, transcript expression of frataxin is highly correlated with that of PGC-1α in Friedreich Ataxia and control cells, and knock down of frataxin in cell culture also decreases transcript expression of PGC-1α.
Tuesday, January 20, 2015
Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials
Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials. Giovanni Pagano, Annarita Aiello Talamanca, Giuseppe Castello, Mario D. Cordero, Marco d'Ischia, Maria Nicola Gadaleta, Federico V. Pallardó, Sandra Petrović, Luca Tiano and Adriana Zatterale; Int. J. Mol. Sci. 2014, 15(11), 20169-20208; doi:10.3390/ijms151120169
OPEN ACCESS, FULL TEXT PDF
OPEN ACCESS, FULL TEXT PDF
Mammalian frataxin directly enhances sulfur transfer of NFS1 persulfide to both ISCU and free thiols.
Mammalian frataxin directly enhances sulfur transfer of NFS1 persulfide to both ISCU and free thiols. Aubérie Parent, Xavier Elduque, David Cornu, Laura Belot, Jean-Pierre Le Caer, Anna Grandas, Michel B. Toledano, Benoit D’Autréaux; Nature Communications 6, doi:10.1038/ncomms6686, Published 19 January 2015
These data raise important questions on the physiological mechanism of Fe-S cluster assembly and point to a unique function of frataxin as an enhancer of sulfur transfer within the NFS1–ISD11–ISCU complex.
These data raise important questions on the physiological mechanism of Fe-S cluster assembly and point to a unique function of frataxin as an enhancer of sulfur transfer within the NFS1–ISD11–ISCU complex.
Subscribe to:
Posts (Atom)
